The stunning clodronate

Not only macrophages, but also neutrophils, are a main target of clodronate. In this issue of JEM, Culemann et al. (2023. J. Exp. Med. https://doi.org/10.1084/jem.20220525) demonstrate that anti-inflammatory effects of clodronate liposomes are driven via stunning of polymorphonuclear neutrophils and...

Descripción completa

Detalles Bibliográficos
Autor principal: Mass, Elvira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2023
Materias:
Insights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067525/
https://www.ncbi.nlm.nih.gov/pubmed/36976179
http://dx.doi.org/10.1084/jem.20230339
_version_ 1785018492510011392
author Mass, Elvira
author_facet Mass, Elvira
author_sort Mass, Elvira
collection PubMed
description Not only macrophages, but also neutrophils, are a main target of clodronate. In this issue of JEM, Culemann et al. (2023. J. Exp. Med. https://doi.org/10.1084/jem.20220525) demonstrate that anti-inflammatory effects of clodronate liposomes are driven via stunning of polymorphonuclear neutrophils and not solely through depletion of macrophages.
format Online
Article
Text
id pubmed-10067525
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-100675252023-09-28 The stunning clodronate Mass, Elvira J Exp Med Insights Not only macrophages, but also neutrophils, are a main target of clodronate. In this issue of JEM, Culemann et al. (2023. J. Exp. Med. https://doi.org/10.1084/jem.20220525) demonstrate that anti-inflammatory effects of clodronate liposomes are driven via stunning of polymorphonuclear neutrophils and not solely through depletion of macrophages. Rockefeller University Press 2023-03-28 /pmc/articles/PMC10067525/ /pubmed/36976179 http://dx.doi.org/10.1084/jem.20230339 Text en © 2023 Mass https://creativecommons.org/licenses/by-nc-sa/4.0/http://www.rupress.org/terms/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Insights
Mass, Elvira
The stunning clodronate
title The stunning clodronate
title_full The stunning clodronate
title_fullStr The stunning clodronate
title_full_unstemmed The stunning clodronate
title_short The stunning clodronate
title_sort stunning clodronate
topic Insights
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067525/
https://www.ncbi.nlm.nih.gov/pubmed/36976179
http://dx.doi.org/10.1084/jem.20230339
work_keys_str_mv AT masselvira thestunningclodronate
AT masselvira stunningclodronate

Ejemplares similares